Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trialBrian G. Feagan, Laurent Peyrin‐Biroulet, Silvio Danese et al.|The Lancet|2021Cited by 452
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction StudyLaurent Peyrin‐Biroulet, Toshimitsu Fujii, Rebbecca Wilson et al.|Gastroenterology|2023Cited by 97
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialSilvio Danese, Wit Danilkiewicz, Remo Panaccione et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 72
Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case SeriesFrank Phillips, Shaji Sebastian, Bram Verstockt et al.|Journal of Crohn s and Colitis|2021Cited by 15